Liver disease represents a growing global health burden. The development of in vitro liver models which allow the study of disease and the prediction of metabolism and drug-induced liver injury in humans remains a challenge. The maintenance of functional primary hepatocytes cultures, the parenchymal cell of the liver, has historically been difficult with dedifferentiation and the consequent loss of hepatic function limiting utility. The desire for longer term functional liver cultures sparked the development of numerous systems, including collagen sandwiches, spheroids, micropatterned co-cultures and liver microphysiological systems. This review will focus on liver microphysiological systems, often referred to as liver-on-a-chip, and broaden to include platforms with interconnected microphysiological systems or multi-organ-chips. The interconnection of microphysiological systems presents the opportunity to explore system level effects, investigate organ cross talk, and address questions which were previously the preserve of animal experimentation. As a field, microphysiological systems have reached a level of maturity suitable for commercialization and consequent evaluation by a wider community of users, in academia and the pharmaceutical industry. Here scientific, operational, and organizational considerations relevant to the wider adoption of microphysiological systems will be discussed. Applications in which microphysiological systems might offer unique scientific insights or enable studies currently feasible only with animal models are described, and challenges which might be addressed to enable wider adoption of the technologies are highlighted. A path forward which envisions the development of microphysiological systems in partnerships between academia, vendors and industry, is proposed.
Impact statement
Microphysiological systems are in vitro models of human tissues and organs. These systems have advanced rapidly in recent years and are now being commercialized. To achieve wide adoption in the biological and pharmaceutical research communities, microphysiological systems must provide unique insights which translate to humans. This will be achieved by identifying key applications and making microphysiological systems intuitive to use.
GodoyPHewittNJAlbrechtUAndersenMEAnsariNBhattacharyaSBodeJGBolleynJBornerCBottgerJBraeuningABudinskyRABurkhardtBCameronNRCamussiGChoCSChoiYJCraig RowlandsJDahmenUDammGDirschODonatoMTDongJDooleySDrasdoDEakinsRFerreiraKSFonsatoVFraczekJGebhardtRGibsonAGlanemannMGoldringCEGomez-LechonMJGroothuisGMGustavssonLGuyotCHallifaxDHammadSHaywardAHaussingerDHellerbrandCHewittPHoehmeSHolzhutterHGHoustonJBHrachJItoKJaeschkeHKeitelVKelmJMKevin ParkBKordesCKullak-UblickGALeCluyseELLuPLuebke-WheelerJLutzAMaltmanDJMatz-SojaMMcMullenPMerfortIMessnerSMeyerCMwinyiJNaisbittDJNusslerAKOlingaPPampaloniFPiJPlutaLPrzyborskiSARamachandranARogiersVRoweCSchelcherCSchmichKSchwarzMSinghBStelzerEHStiegerBStoberRSugiyamaYTettaCThaslerWEVanhaeckeTVinkenMWeissTSWideraAWoodsCGXuJJYarboroughKMHengstlerJG. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol2013; 87: 1315–530.
2.
LeCluyseELWitekRPAndersenMEPowersMJ. Organotypic liver culture models: meeting current challenges in toxicity testing. Crit Rev Toxicol2012; 42: 501–48.
3.
UllrichABergCHengstlerJGRungeD. Use of a standardised and validated long-term human hepatocyte culture system for repetitive analyses of drugs: repeated administrations of acetaminophen reduces albumin and urea secretion. ALTEX2007; 24: 35–40.
4.
RyanCMCarterEAJenkinsRLSterlingLMYarmushMLMaltRATompkinsRG. Isolation and long-term culture of human hepatocytes. Surgery1993; 113: 48–54.
5.
KonoYYangSRobertsEA. Extended primary culture of human hepatocytes in a collagen gel sandwich system. In Vitro Cell Dev Biol Anim1997; 33: 467–72.
6.
KhetaniSRBhatiaSN. Microscale culture of human liver cells for drug development. Nat Biotechnol2008; 26: 120–6.
7.
MessnerSAgarkovaIMoritzWKelmJM. Multi-cell type human liver microtissues for hepatotoxicity testing. Arch Toxicol2013; 87: 209–13.
8.
BellCCHendriksDFMoroSMEllisEWalshJRenblomAFredriksson PuigvertLDankersACJacobsFSnoeysJSison-YoungRLJenkinsRENordlingAMkrtchianSParkBKKitteringhamNRGoldringCELauschkeVMIngelman-SundbergM. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Sci Rep2016; 6: 25187–25187.
9.
SivaramanALeachJKTownsendSIidaTHoganBJStolzDBFryRSamsonLDTannenbaumSRGriffithLG. A microscale in vitro physiological model of the liver: predictive screens for drug metabolism and enzyme induction. Curr Drug Metab2005; 6: 569–91.
10.
MaherSPCrouseRBConwayAJBannisterECAchyutaAKClarkAYSinatraFLCuiffiJDAdamsJHKyleDESaadiWM. Microphysical space of a liver sinusoid device enables simplified long-term maintenance of chimeric mouse-expanded human hepatocytes. Biomed Microdevices2014; 16: 727–36.
11.
WheelerSEClarkAMTaylorDPYoungCLPillaiVCStolzDBVenkataramananRLauffenburgerDGriffithLWellsA. Spontaneous dormancy of metastatic breast cancer cells in an all human liver microphysiologic system. Br J Cancer2014; 111: 2342–50.
12.
ProdanovLJindalRBaleSSHegdeMMcCartyWJGolbergIBhushanAYarmushMLUstaOB. Long-term maintenance of a microfluidic 3D human liver sinusoid. Biotechnol Bioeng2016; 113: 241–6.
13.
DomanskyKInmanWSerdyJDashALimMHGriffithLG. Perfused multiwell plate for 3D liver tissue engineering. Lab Chip2010; 10: 51–8.
14.
EbrahimkhaniMRNeimanJARaredonMSHughesDJGriffithLG. Bioreactor technologies to support liver function in vitro. Adv Drug Deliv Rev2014; 69-70: 132–57.
15.
BaleSSVernettiLSenutovitchNJindalRHegdeMGoughAMcCartyWJBakanABhushanAShunTYGolbergIDeBiasioRUstaOBTaylorDLYarmushML. In vitro platforms for evaluating liver toxicity. Exp Biol Med (Maywood)2014; 239: 1180–91.
16.
LauschkeVMHendriksDFBellCCAnderssonTBIngelman-SundbergM. Novel 3D culture systems for studies of human liver function and assessments of the hepatotoxicity of drugs and drug candidates. Chem Res Toxicol2016; 29: 1936–55.
17.
NovikEMaguireTJChaoPChengKCYarmushML. A microfluidic hepatic coculture platform for cell-based drug metabolism studies. Biochem Pharmacol2010; 79: 1036–44.
18.
KhetaniSRKanchagarCUkairoOKrzyzewskiSMooreAShiJAoyamaSAleoMWillY. Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans. Toxicol Sci2013; 132: 107–17.
19.
WangWWKhetaniSRKrzyzewskiSDuignanDBObachRS. Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites. Drug Metab Dispos2010; 38: 1900–5.
20.
ChanTSYuHMooreAKhetaniSRTweedieD. Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac. Drug Metab Dispos2013; 41: 2024–32.
21.
AtienzarFANovikEIGeretsHHParekhADelatourCCardenasAMacDonaldJYarmushMLDhalluinS. Predictivity of dog co-culture model, primary human hepatocytes and HepG2 cells for the detection of hepatotoxic drugs in humans. Toxicol Appl Pharmacol2014; 275: 44–61.
22.
KratochwilNAMeilleCFowlerSKlammersFEkicilerAMolitorBSimonSWalterIMcGinnisCWaltherJLeonardBTriyatniMJavanbakhtHFunkCSchulerFLaveTParrottNJ. Metabolic profiling of human long-term liver models and hepatic clearance predictions from in vitro data using nonlinear mixed-effects modeling. AAPS J2017; 19: 534–50.
23.
HendriksDFFredriksson PuigvertLMessnerSMortizWIngelman-SundbergM. Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability. Sci Rep2016; 6: 35434–35434.
24.
KostadinovaRBoessFApplegateDSuterLWeiserTSingerTNaughtonBRothA. A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. Toxicol Appl Pharmacol2013; 268: 1–16.
25.
SchutteMFoxBBaradezMODevonshireAMinguezJBokhariMPrzyborskiSMarshallD. Rat primary hepatocytes show enhanced performance and sensitivity to acetaminophen during three-dimensional culture on a polystyrene scaffold designed for routine use. Assay Drug Dev Technol2011; 9: 475–86.
26.
DashAInmanWHoffmasterKSevidalSKellyJObachRSGriffithLGTannenbaumSR. Liver tissue engineering in the evaluation of drug safety. Expert Opin Drug Metab Toxicol2009; 5: 1159–74.
27.
KostrzewskiTCornforthTSnowSAOuro-GnaoLRoweCLargeEMHughesDJ. Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease. World J Gastroenterol2017; 23: 204–15.
28.
ChaoPMaguireTNovikEChengKCYarmushML. Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human. Biochem Pharmacol2009; 78: 625–32.
29.
JangMNeuzilPVolkTManzAKleberA. On-chip three-dimensional cell culture in phaseguides improves hepatocyte functions in vitro. Biomicrofluidics2015; 9: 034113–034113.
30.
VivaresASalle-LefortSArabeyre-FabreCNgoRPenarierGBremondMMolinerPGallasJFFabreGKlieberS. Morphological behaviour and metabolic capacity of cryopreserved human primary hepatocytes cultivated in a perfused multiwell device. Xenobiotica2015; 45: 29–44.
31.
LongTJCosgrovePADunnRT2ndStolzDBHamadehHAfshariCMcBrideHGriffithLG. Modeling therapeutic antibody-small molecule drug-drug interactions using a three-dimensional perfusable human liver coculture platform. Drug Metab Dispos2016; 44: 1940–8.
32.
BaleSSSridharanGVGolbergIProdanovLMcCartyWJUstaOBJindalRYarmushML. A novel low-volume two-chamber microfabricated platform for evaluating drug metabolism and toxicity. Technology (Singap World Sci)2015; 3: 155–62.
33.
MarxUAnderssonTBBahinskiABeilmannMBekenSCasseeFRCiritMDaneshianMFitzpatrickSFreyOGaertnerCGieseCGriffithLHartungTHeringaMBHoengJde JongWHKojimaHKuehnlJLeistMLuchAMaschmeyerISakharovDSipsAJSteger-HartmannTTagleDATonevitskyATralauTTsybSvan de StolpeAVandebrielRVultoPWangJWiestJRodenburgMRothA. Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing. ALTEX2016; 33: 272–321.
34.
BavliDPrillSEzraELevyGCohenMVinkenMVanfleterenJJaegerMNahmiasY. Real-time monitoring of metabolic function in liver-on-chip microdevices tracks the dynamics of mitochondrial dysfunction. Proc Natl Acad Sci U S A2016; 113: E2231–40.
35.
ClarkAMWheelerSETaylorDPPillaiVCYoungCLPrantil-BaunRNguyenTStolzDBBorensteinJTLauffenburgerDAVenkataramananRGriffithLGWellsA. A microphysiological system model of therapy for liver micrometastases. Exp Biol Med (Maywood)2014; 239: 1170–9.
36.
WikswoJPBlockFE3rdCliffelDEGoodwinCRMarascoCCMarkovDAMcLeanDLMcLeanJAMcKenzieJRReisererRSSamsonPCSchafferDKSealeKTSherrodSD. Engineering challenges for instrumenting and controlling integrated organ-on-chip systems. IEEE Trans Biomed Eng2013; 60: 682–90.
37.
MarascoCCEndersJRSealeKTMcLeanJAWikswoJP. Real-time cellular exometabolome analysis with a microfluidic-mass spectrometry platform. PLoS One2015; 10: e0117685–e0117685.
38.
HuhDLeslieDCMatthewsBDFraserJPJurekSHamiltonGAThorneloeKSMcAlexanderMAIngberDE. A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice. Sci Transl Med2012; 4: 159ra47–159ra47.
39.
JungermannKKietzmannT. Oxygen: modulator of metabolic zonation and disease of the liver. Hepatology2000; 31: 255–60.
40.
AllenJWKhetaniSRBhatiaSN. In vitro zonation and toxicity in a hepatocyte bioreactor. Toxicol Sci2005; 84: 110–9.
41.
RotemATonerMTompkinsRGYarmushML. Oxygen uptake rates in cultured rat hepatocytes. Biotechnol Bioeng1992; 40: 1286–91.
42.
SarkarURivera-BurgosDLargeEMHughesDJRavindraKCDyerRLEbrahimkhaniMRWishnokJSGriffithLGTannenbaumSR. Metabolite profiling and pharmacokinetic evaluation of hydrocortisone in a perfused three-dimensional human liver bioreactor. Drug Metab Dispos2015; 43: 1091–9.
43.
BaleSSGeertsSJindalRYarmushML. Isolation and co-culture of rat parenchymal and non-parenchymal liver cells to evaluate cellular interactions and response. Sci Rep2016; 6: 25329–25329.
44.
NguyenTVUkairoOKhetaniSRMcVayMKanchagarCSeghezziWAyanogluGIrrechukwuOEversR. Establishment of a hepatocyte-kupffer cell coculture model for assessment of proinflammatory cytokine effects on metabolizing enzymes and drug transporters. Drug Metab Dispos2015; 43: 774–85.
45.
RennertKSteinbornSGrogerMUngerbockBJankAMEhgartnerJNietzscheSDingerJKiehntopfMFunkeHPetersFTLuppAGartnerCMayrTBauerMHuberOMosigAS. A microfluidically perfused three dimensional human liver model. Biomaterials2015; 71: 119–31.
46.
RothRAGaneyPE. Intrinsic versus idiosyncratic drug-induced hepatotoxicity–two villains or one?J Pharmacol Exp Ther2010; 332: 692–7.
47.
ShawPJGaneyPERothRA. Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol Sci2010; 118: 7–18.
48.
ThanNNNewsomePN. A concise review of non-alcoholic fatty liver disease. Atherosclerosis2015; 239: 192–202.
49.
WillebrordsJPereiraIVMaesMCrespo YanguasSColleIVan Den BosscheBDa SilvaTCde OliveiraCPAndrausWAlvesVACogliatiBVinkenM. Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. Prog Lipid Res2015; 59: 106–25.
50.
RashidSTCorbineauSHannanNMarciniakSJMirandaEAlexanderGHuang-DoranIGriffinJAhrlund-RichterLSkepperJSempleRWeberALomasDAVallierL. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest2010; 120: 3127–36.
51.
YangKPfeiferNDKockKBrouwerKL. Species differences in hepatobiliary disposition of taurocholic acid in human and rat sandwich-cultured hepatocytes: implications for drug-induced liver injury. J Pharmacol Exp Ther2015; 353: 415–23.
52.
WinnikeJHPediaditakisPWolakJEMcClellandREWatkinsPBMacdonaldJM. Stable isotope resolved metabolomics of primary human hepatocytes reveals a stressed phenotype. Metabolomics2012; 8: 34–49.
53.
SunmanJAHawkeRLLeCluyseELKashubaAD. Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos2004; 32: 359–63.
54.
HughesDJCuiZFieldRWTirlapurUK. In situ three-dimensional characterization of membrane fouling by protein suspensions using multiphoton microscopy. Langmuir2006; 22: 6266–72.
55.
GhanemAShulerML. Combining cell culture analogue reactor designs and PBPK models to probe mechanisms of naphthalene toxicity. Biotechnol Prog2000; 16: 334–45.
56.
ViravaidyaKSinAShulerML. Development of a microscale cell culture analog to probe naphthalene toxicity. Biotechnol Prog2004; 20: 316–23.
57.
LasserKEAllenPDWoolhandlerSJHimmelsteinDUWolfeSMBorDH. Timing of new black box warnings and withdrawals for prescription medications. JAMA2002; 287: 2215–20.
58.
Vunjak-NovakovicGBhatiaSChenCHirschiK. HeLiVa platform: integrated heart-liver-vascular systems for drug testing in human health and disease. Stem Cell Res Ther2013; 1: S8–S8.
59.
OleagaCBernabiniCSmithASSrinivasanBJacksonMMcLambWPlattVBridgesRCaiYSanthanamNBerryBNajjarSAkandaNGuoXMartinCEkmanGEschMBLangerJOuedraogoGCotovioJBretonLShulerMLHickmanJJ. Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs. Sci Rep2016; 6: 20030–20030.
60.
MaschmeyerIHasenbergTJaenickeALindnerMLorenzAKZechJGarbeLASonntagFHaydenPAyehunieSLausterRMarxUMaterneEM. Chip-based human liver-intestine and liver-skin co-cultures – a first step toward systemic repeated dose substance testing in vitro. Eur J Pharm Biopharm2015; 95: 77–87.
61.
ImuraYSatoKYoshimuraE. Micro total bioassay system for ingested substances: assessment of intestinal absorption, hepatic metabolism, and bioactivity. Anal Chem2010; 82: 9983–8.
62.
EschMBUenoHApplegateDRShulerML. Modular, pumpless body-on-a-chip platform for the co-culture of GI tract epithelium and 3D primary liver tissue. Lab Chip2016; 16: 2719–29.
63.
KimJYFluriDAMarchanRBoonenKMohantySSinghPHammadSLanduytBHengstlerJGKelmJMHierlemannAFreyO. 3D spherical microtissues and microfluidic technology for multi-tissue experiments and analysis. J Biotechnol2015; 205: 24–35.
64.
WikswoJPCurtisELEagletonZEEvansBCKoleAHofmeisterLHMatloffWJ. Scaling and systems biology for integrating multiple organs-on-a-chip. Lab Chip2013; 13: 3496–511.
65.
AbaciHEShulerML. Human-on-a-chip design strategies and principles for physiologically based pharmacokinetics/pharmacodynamics modeling. Integr Biol (Camb)2015; 7: 383–91.
66.
TsamandourasNKostrzewskiTStokesCLGriffithLGHughesDJCiritM. Quantitative assessment of population variability in hepatic drug metabolism using a perfused three-dimensional human liver microphysiological system. J Pharmacol Exp Ther2017; 360: 95–105.
67.
CosgroveBDGriffithLGLauffenburgerDA. Fusing tissue engineering and systems biology toward fulfilling their promise. Cell Mol Bioeng2008; 1: 33–41.
68.
MillerPGShulerML. Design and demonstration of a pumpless 14 compartment microphysiological system. Biotechnol Bioeng2016; 113: 2213–27.
69.
van MidwoudPMJanseAMeremaMTGroothuisGMVerpoorteE. Comparison of biocompatibility and adsorption properties of different plastics for advanced microfluidic cell and tissue culture models. Anal Chem2012; 84: 3938–44.
WangJDDouvilleNJTakayamaSElSayedM. Quantitative analysis of molecular absorption into PDMS microfluidic channels. Ann Biomed Eng2012; 40: 1862–73.
72.
ZhouJEllisAVVoelckerNH. Recent developments in PDMS surface modification for microfluidic devices. Electrophoresis2010; 31: 2–16.
73.
DomanskyKLeslieDCMcKinneyJFraserJPSlizJDHamkins-IndikTHamiltonGABahinskiAIngberDE. Clear castable polyurethane elastomer for fabrication of microfluidic devices. Lab Chip2013; 13: 3956–64.
74.
KimJYFluriDAKelmJMHierlemannAFreyO. 96-well format-based microfluidic platform for parallel interconnection of multiple multicellular spheroids. J Lab Autom2015; 20: 274–82.
75.
MathurALoskillPShaoKHuebschNHongSMarcusSGMarksNMandegarMConklinBRLeeLPHealyKE. Human iPSC-based cardiac microphysiological system for drug screening applications. Sci Rep2015; 5: 8883–8883.
